BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $93,135.96 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,156 shares of BridgeBio Pharma stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $93,135.96. Following the completion of the transaction, the chief financial officer now directly owns 93,758 shares in the company, valued at $2,101,116.78. The trade was a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

BridgeBio Pharma Price Performance

BBIO traded up $0.50 during trading on Wednesday, hitting $23.04. The company had a trading volume of 1,395,889 shares, compared to its average volume of 1,852,762. The company has a market cap of $4.35 billion, a PE ratio of -9.56 and a beta of 1.09. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $44.32. The business has a 50-day moving average of $25.18 and a 200-day moving average of $26.33.

Institutional Trading of BridgeBio Pharma

Several institutional investors have recently added to or reduced their stakes in the business. Bfsg LLC boosted its holdings in shares of BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after buying an additional 790 shares during the period. Headlands Technologies LLC acquired a new position in BridgeBio Pharma during the 2nd quarter valued at approximately $48,000. Values First Advisors Inc. bought a new position in BridgeBio Pharma during the 3rd quarter worth $57,000. CWM LLC increased its position in BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after buying an additional 1,964 shares during the period. Finally, EntryPoint Capital LLC bought a new stake in BridgeBio Pharma in the first quarter valued at $117,000. Institutional investors own 99.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on BBIO shares. Oppenheimer initiated coverage on shares of BridgeBio Pharma in a research report on Thursday, October 3rd. They set a “market perform” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $70.00 price target on shares of BridgeBio Pharma in a research report on Monday, September 16th. Piper Sandler assumed coverage on BridgeBio Pharma in a research note on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 price objective for the company. Evercore ISI lowered their target price on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, Leerink Partners cut their price target on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.57.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.